--- title: 'Clinical Daily Summary: What Happened on November 10, 2026' headline: Novartis’ pelacarsen lowered Lp(a) but did not improve cardiovascular outcomes description: Vir’s hepatitis D combination met its Phase III primary endpoint. Zura stopped a separate drug program after a Phase II trial missed its goals. url: https://thebench.bio/news/clinical/2026-11-10 topic: clinical date: '2026-11-10' covers: - '2026-11-10' date_published: '2026-11-10T12:03:19Z' date_modified: '2026-11-10T12:03:19Z' tags: - Clinical - Industry sources: 5 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on November 10, 2026 **Novartis’ pelacarsen lowered Lp(a) but did not improve cardiovascular outcomes** Vir’s hepatitis D combination met its Phase III primary endpoint. Zura stopped a separate drug program after a Phase II trial missed its goals. ## Today in brief Pelacarsen lowered Lp(a) by nearly 80% after 12 months in Novartis’ Phase III HORIZON study, but cardiovascular outcomes did not improve. [1] Vir said its hepatitis D combination met the primary endpoint in a Phase III trial, with 44% of treated participants showing undetectable virus and normalized ALT at week 48. [2] Zura Bio discontinued tibulizumab for hidradenitis suppurativa after a Phase II trial missed its primary and secondary endpoints. [3] ## Pelacarsen lowered Lp(a), without reducing cardiovascular events In the Phase III HORIZON study, pelacarsen lowered Lp(a) by an average of nearly 80% after 12 months of treatment. [1] The reduction did not improve cardiovascular outcomes across multiple endpoints or subgroup analyses. [1] ## Vir’s hepatitis D combination met its Phase III primary endpoint Vir Biotechnology said its combination of elebsiran and tobevibart met the primary endpoint in ECLIPSE 1, a Phase III trial in chronic hepatitis delta. [2] At week 48, 44% of participants receiving monthly injections had undetectable virus and normalized ALT. None in the delayed-treatment group had both outcomes at week 12. [2] The combination also met a key secondary endpoint. At week 48, 79% of treated participants had undetectable viral levels, compared with none in the comparator arm. [2] One treatment-related Grade 3 event, a temporary decrease in neutrophils, resolved within 15 days. No participant interrupted or stopped treatment because of an adverse event. [2] In the Phase II SOLSTICE study, all 28 participants who completed 96 weeks had undetectable viral levels. [2] An exploratory group of 10 people who stopped treatment after 96 weeks of suppression maintained a viral response through week 12 without rebound. [2] ## Zura ends tibulizumab program after Phase II trial misses endpoints Zura Bio discontinued tibulizumab for hidradenitis suppurativa after its 247-person TibuSHIELD study missed its primary and secondary endpoints. [3] At week 16, abscess and inflammatory nodule counts fell by 58.1% and 56.0% in the two dose groups, close to the 52.5% reduction with placebo. [3] Secondary measures, including HiSCR50 and HiSCR75, also showed no meaningful separation from placebo. [3] One participant in the higher-dose group died of cardiac arrest. The site investigator judged the death unrelated to treatment and cited multiple cardiovascular risk factors. [3] Zura plans to continue testing tibulizumab in systemic sclerosis, with topline Phase II results expected in the first half of 2027. [3] ## Also worth knowing - After one dose of its CIDEB-targeting siRNA, Regeneron reported liver-fat reductions of 58% to 80% at week 36 across dose groups, compared with 2.9% with placebo, in a Phase I/II MASLD study. [4] - START and Rome’s Regina Elena National Cancer Institute are partnering to establish an early-phase oncology trial site in Italy, START’s first in the country. [5] ## The day in numbers - **Nearly 80%**: Average reduction in Lp(a) after 12 months of pelacarsen in HORIZON, without improved cardiovascular outcomes. [1] - **44%**: Share of ECLIPSE 1 participants receiving Vir’s combination who had undetectable virus and normalized ALT at week 48. [2] ## Also published - [ACT Brief: China’s Startup Timelines, AI-Drafted Clinical Study Reports, and Bimzelx Psoriatic Arthritis Data](), Applied Clinical Trials - [Where AI Can Strengthen Clinical Research, and Where Patient Input is More Important](), Pharmaceutical Executive - [\Next-generation KRAS G12C inhibitor improves survival in lung cancer\](), Nature Medicine - [Vir hepatitis D drug succeeds in first pivotal study](), BioPharma Dive - [Novartis' pelacarsen fail raises questions for other drugs](), pharmaphorum ## Sources 1. [Novartis’ full HORIZON data deepen doubts about Lp(a) as a target](), BioCentury, 2026-11-10 2. [Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials](), Clinical Trials Arena, 2026-11-10 3. [Zura Bio discontinues tibulizumab in HS after Phase II trial failure](), Clinical Trials Arena, 2026-11-10 4. [Dose-dependent liver fat reductions support CIDEB as a target in MASLD](), BioCentury, 2026-11-10 5. [START and Rome cancer institute partner to expand early-phase trial access in Italy](), Pharmafile, 2026-11-10 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: